MGMT Methylation Analysis in Glioblastoma Treatment Outcomes

The methylation status of the O6‐methylguanine‐DNA methyltransferase (MGMT) gene promoter is a pivotal predictive and prognostic biomarker in glioblastoma management. Epigenetic silencing of MGMT via promoter methylation compromises the tumour’s DNA‐repair capacity, thereby enhancing sensitivity to the alkylating agent temozolomide. Accurate, quantitative assessment of methylation at specific CpG sites—using techniques such as pyrosequencing or methylation‐specific PCR—enables stratification of patients into methylated and unmethylated groups, guiding treatment intensity and reducing unnecessary toxicity. Recent methodological refinements have identified critical regions within the promoter and adjacent enhancer elements whose methylation correlates strongly with overall survival. Incorporating combined promoter–enhancer methylation profiles into clinical workflows promises more precise prediction of therapeutic response and supports the development of risk‐adapted protocols worldwide.

Research from Nature Portfolio

No recent Nature Portfolio content available.

MGMT Methylation Analysis in Glioblastoma Treatment Outcomes publication trend

The graph below shows the total number of articles in mgmt methylation analysis in glioblastoma treatment outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

MGMT promoter methylation: Addition of methyl groups to cytosine residues in the MGMT gene promoter leading to transcriptional silencing and increased chemotherapy sensitivity.

CpG site: A cytosine–phosphate–guanine dinucleotide in DNA, commonly targeted for methylation.

Enhancer region: A DNA segment that augments gene transcription, potentially from a distance.

Pyrosequencing: A quantitative sequencing method used to determine methylation levels at specific CpG sites.

Temozolomide: An alkylating agent that induces DNA damage; its efficacy in glioblastoma is modulated by MGMT activity.

References

1. No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients. Neuro-Oncology (2024).
2. MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value. Acta Neuropathologica Communications (2023).
3. Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma. Cells (2023).
4. MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. Journal of Translational Medicine (2012).